The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Upgrades 2025 full-year CDMO sales and margin outlook
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Subscribe To Our Newsletter & Stay Updated
